** Massachusetts-based drug developer Neuphoria Therapeutics NEUP.O rises 3.31% to $4.65 in morning trade
** Co, which develops treatments for brain and mental health disorders, says it is due to receive $15 million milestone payment from Merck MRK.N
** The payment is triggered by the start of a mid-stage study for the treatment of Merck's Alzheimer's disease dementia
** The study is estimated to complete on July 20, 2027
** The study is to test if the experimental drug, MK-1167, given along with another therapy that affects memory, which can improve symptoms of Alzheimer's disease dementia such as memory and mental activity
** NEUP is eligible to receive up to $450 million in additional milestone payments if certain developments are achieved
** In the last 12 months, the stock down 70%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.